Every concentrated position is a story about how someone got wealthy, told by someone who has not yet decided whether to stay that way. The stock did something extraordinary for you. What you owe it in return is nothing. This note is about deciding how much to keep, how fast to reduce the rest, and which tools to use.
A concentrated position is a risk problem, a tax problem, and an identity problem, in that order of importance and the reverse order of how much attention they get. People fixate on the tax problem because it has numbers. The risk problem gets a shrug because the stock has only ever gone up, which is precisely how it became a concentration. The identity problem goes unmentioned because it sounds soft, then drives every decision.
My operating rule: solve for risk first, optimize taxes second, and acknowledge the feelings without letting them decide.
Since 1926, roughly four percent of U.S. stocks account for all of the stock market's net wealth creation above Treasury bills. The majority of individual stocks, over their full public lives, returned less than cash.1 The market's famous long-run compounding is a property of the portfolio, not of the typical stock inside it. Holding one name is not a smaller version of holding the market. It is a different bet with a different distribution, and the distribution has a long, ugly left side.
Two objections come up in nearly every first meeting, so let me handle them here. "But I know this company." You know the company; the market knows the company too, and everything both of you can legally know is already in the price. What remains is conviction, and conviction is not information. "But it keeps going up." So did every position that later became a case study. A great company and a great stock return from today's price are two different claims; the second is much harder.
The magnitudes matter. A single mid-cap name commonly runs 40 to 60 percent annualized volatility; a clinical-stage biotech runs higher, with binary events that can reprice it 40 percent overnight. Positions like that routinely lose half their value at some point, including on the way to good outcomes.
Before touching any tactic, compute one figure: the amount that, invested boringly, sustains the life you actually want. Housing, education, the annual spend, the buffer. Call it the walk-away number. Everything up to that number gets protected first. Concentration with money above the line is a choice you are entitled to make. Concentration with money below the line risks the essentials for upside you do not need.
Rules of thumb say to keep any single stock to 10 or 15 percent of your net worth. Rules of thumb do not know your mortgage, your risk appetite, or your vesting schedule, which is why the walk-away number comes first and the percentage second.
The real decision is not whether to diversify but how fast, and it is a trade between a known cost and an unknown one. The known cost: long-term capital gains at 23.8 percent federal plus up to 13.3 percent in California, paid once, on gains only. The unknown cost: the position's volatility, charged continuously against the whole value, in either direction, with no cap.
Concrete version. A $5 million position with a $4 million gain owes roughly $1.4 million if liquidated in one shot by a top-bracket Californian. Painful, bounded, and then over. The same position at 60 percent volatility can shed $2.5 million in a bad year without violating any law of statistics, and in biotech that can happen on a Tuesday. The tax is a bounded, one-time cost; the risk is unbounded and continuous. The market does not know your cost basis.
None of which means liquidating everything at Monday's open. Multi-year schedules that respect brackets, harvest losses, and route the charitable dollars intelligently usually recover a meaningful share of the tax cost. Just be honest about what the schedule is: risk you are choosing to keep, priced in years. Stretch it for bracket reasons. Do not stretch it to avoid a feeling.
A hypothetical, and I want to be plain that it is a composite illustration, not a client of the firm. A 38-year-old scientist has $5 million of net worth, $4 million of it in her employer's stock after an IPO. Her walk-away number pencils out near $3 million. The framework says her current arrangement bets the walk-away money on one clinical-stage ticker, so the plan brings the position under 25 percent of net worth within 18 months: a 10b5-1 schedule through two tax years, the year's charitable giving switched from cash to shares, sale proceeds landing in a diversified sleeve that harvests losses along the way, and a QSBS review before any of it starts, because if some lots qualify, the order of sales changes. Eighteen months later the stock can triple or crater and her life is fine either way. That is the entire objective.
If a single ticker is carrying more of your net worth than you would choose from scratch, that is a solvable problem with more good tools than most people expect. The introductory call is 30 minutes, and you will leave with the framework applied to your numbers.
1Bessembinder, H. (2018). "Do Stocks Outperform Treasury Bills?" Journal of Financial Economics, 129(3).
2IRC §1259 (constructive sales of appreciated financial positions).
This note is educational and general in nature. It is not individualized investment, tax, or legal advice, and figures reflect federal and California law as of July 2026. The example shown is hypothetical, simplified, and not representative of any client. Diversification does not guarantee a profit or protect against loss. Investing involves risk, including the possible loss of principal.
Financial Professionals may only conduct business with residents of the states or jurisdictions in which they are properly registered, licensed or exempt from registration and not all of the securities, products and services mentioned are available in every state or jurisdiction.
Securities offered through Registered Representatives of Cambridge Investment Research, Inc., a broker-dealer, member FINRA/SIPC. Advisory services through Cambridge Investment Research Advisors, Inc., a Registered Investment Adviser. Cambridge and Bayes Wealth are not affiliated. Check the background of this investment professional on FINRA's BrokerCheck.
© 2026 Bayes Wealth. All rights reserved.